Statins: Effects beyond cholesterol lowering

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 5, Issue 2, 2005, Pages 111-113

  Shen, Garry X ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; CYTOCHROME P450; FARNESYL DIPHOSPHATE; FIBRINOGEN; GERANYLGERANYL PYROPHOSPHATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVALONIC ACID; MEVINOLIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PRAVASTATIN; PROTHROMBIN; RAC PROTEIN; RAP PROTEIN; RAS PROTEIN; RHO FACTOR; SIMVASTATIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ANGIOPLASTY; ANTIGEN EXPRESSION; APOPTOSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; BLOOD CLOTTING; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; FIBRINOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOMODULATION; INFLAMMATION; INHIBITION KINETICS; INTRACARDIAC THROMBOSIS; ISCHEMIC HEART DISEASE; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; META ANALYSIS; METABOLIC SYNDROME X; MOOD DISORDER; MORTALITY; MULTIPLE SCLEROSIS; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRESCRIPTION; PROGNOSIS; PROTEIN PROCESSING; RESTENOSIS; RETINA MACULA AGE RELATED DEGENERATION; RHABDOMYOLYSIS; SIGNAL TRANSDUCTION; STROKE; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; T LYMPHOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

APOPTOSIS; BLOOD COAGULATION; CELL PROLIFERATION; FIBRINOLYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; IMMUNOLOGIC FACTORS; INFLAMMATION; METABOLIC SYNDROME X; OXIDATIVE STRESS; PLATELET ACTIVATION; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 18444400587     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006043586215     Document Type: Editorial

References (36)

1. Witiak, D.T., Kuwano, E., Feller, D.R., Baldwin, J.R., Newman, H.A., Sankrappa, S.K. Synthesis and antilipidemic properties of cis-7-chloro-3a, 8b-dihydro-3a-methylfuro [3,4-b]benzofuran-3(1H)-one, a tricyclic clofibrate related lactone having a structural resemblance to mevalonolactone. J. Med. Chem. 1976, 19, 1214-1220.
2. Cheung, B.M., Lauder, I.J., Lau, C.P., Kumana, C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol. 2004, 57, 640-651.
3. Corsini, A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc. Drugs Ther. 2003, 17, 265-285.
4. Fischer, A., Gutstein, D.E., Fuster, V. Thrombosis and coagulation abnormalities in the acute coronary syndromes. Cardiol. Clin. 1999, 17, 283-294.
5. Ferro, D., Basili, S., Alessandri, C., Mantovani, B., Cordova, C., Violi, F. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. Lancet. 1997, 25, 350:1222.
6. Davignon, J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004, 109(Suppl 1), III39-43.
7. Balk, E.M., Lau, J., Goudas, L.C., Jordan, H.S., Kupelnick, B., Kim, L.U., Karas, R.H. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann. Intern. Med. 2003, 139, 670-682.
8. Ludwig, S., Dharmalingam, S., Erickson-Nesmith, S., Ren, S., Zhu, F., Ma, G.M., Zhao, R., Fenton, J.W. II, Ofosu, F.A., te Velthuis, H., van Mierlo, G., Shen, G.X. Simvastatin reduces plasma levels of prothrombin fragement 1 + 2 and plasminogen activator inhibitor-1 in type 2 diabetes mellitus. Can. J. Diabetes. 2004, 28, 286 (abstract).
9. van Nieuw Amerongen, G.P., van Delft, S., Vermeer, M.A., Collard, J.G., van Hinsbergh, V.W. Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ. Res. 2000, 87, 335-340.
10. Takemoto, M., Liao, J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1712-1719.
11. Comparato, C., Altana, C., Bellosta, S., Baetta, R., Paoletti, R., Corsini, A. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr. Metab. Cardiovasc. Dis. 2001, 111, 328-343.
12. Rosalki, S.B. C-reactive protein. Int. J. Clin. Pract. 2001, 55, 269-270.
13. Ridker, P.M. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation. 2003, 108, e8l-85.
14. Libby, P. Inflammation in atherosclerosis. Nature. 2002, 420, 868-874.
15. McCarty, M.F. Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. Med. Hypotheses. 2003, 60, 634-639.
16. Mach, F. Statins as immunomodulatory agents. Circulation. 2004, 109, II15-17.
17. Baker, D., Adamson, P., Greenwood, J. Potential of statins for the treatment of multiple sclerosis. Lancet Neurol. 2003, 2, 9-10.
18. Stuve, O., Youssef, S., Steinman, L., Zamvil, S.S. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Neurol. 2003, 16, 393-401.
19. Johansen, O., Abdelnoor, M., Brekke, M., Seljeflot, I., Hostmark, A.T., Arnesen, H. Predictors of restenosis after coronary angioplasty. A study on demographic and metabolic variables. Scand. Cardiovasc. J. 2001, 35, 86-91.
20. Negre-Aminou, P., van Vliet, A.K., van Erck, M., van Thiel, G.C., van Leeuwen R.E., Cohen, L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim. Biophys. Acta. 1997, 1345, 259-268.
21. Wilson, H.L., Schwartz, D.M., Bhatt, H.R., McCulloch, C.E., Duncan, J.L. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am. J. Ophthalmol. 2004, 137, 615-624.
22. Jakobisiak, M., Golab, J. Potential antitumor effects of statins (Review). Int. J. Oncol. 2003, 3, 055-1069
23. Strawn, W.B., Ferrario, C.M. Mechanisms linking angiotensin II and atherogenesis. Curr. Opin. Lipidol. 2002, 13, 505-512.
24. Wassmann, S., Laufs, U., Baumer, A.T., Muller, K., Ahlbory, K., Linz, W., Itter, G., Rosen, R., Bohm, M., Nickenig, G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001, 37, 1450-1457.
25. Comparato, C., Altana, C., Nickenig, G., Baumer, A.T., Temur, Y., Kebben, D., Jockenhovel, F., Bohm, M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999, 100, 2131-2134.
26. Ullom-Minnich, P. Strategies to reduce complications of type 2 diabetes. J. Fam. Pract. 2004, 53, 366-375.
27. Kjekshus, J., Pedersen, T.R. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am. J. Cardiol. 1995, 76, 64C-68C.
28. Streja, L., Packard, C.J., Shepherd, J., Cobbe, S., Ford, I. WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). Am. J. Cardiol. 2002, 90, 731-736.
29. Miller, M., Mead, L.A., Kwiterovich, P.O. Jr., Pearson, T.A. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am. J. Cardiol. 1990, 65, 1-5.
30. Ducas, J., Silversides, C., Dembinski, T.C., Chan, M.C., Tate, R., Dick, A., Nixon, P., Ren, S., Shen, G.X. Apolipoprotein(a) phenotypes predict the severity of coronary artery stenosis.Clin. Invest. Med. 2002, 25, 74-82.
31. Deakin, S., Leviev, I., Guernier, S., James, R.W. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 2083-2089.
32. Hokanson, J.E. Hypertriglyceridemia and risk of coronary heart disease. Curr. Cardiol. Rep. 2002, 4, 488-493.
33. Plehn, J.F., Davis, B.R., Sacks, F.M., Rouleau, J.L., Pfeffer, M.A., Bernstein, V., Cuddy, T.E., Moye, L.A., Piller, L.B., Rutherford, J., Simpson, L.M., Braunwald, E. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation. 1999, 99, 216-223.
34. Gotto, A.M. Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am. Heart J. 2002, 144, S33-S42.
35. Moghadasian, M.H. A safety look at currently available statins. Expert. Opin. Drug Saf. 2002, 1, 269-274.
36. Bolego, C., Baetta, R., Bellosta, S., Corsini, A., Paoletti, R. Safety considerations for statins. Curr. Opin. Lipidol. 2002, 13, 637-644.